Lenacapavir, a groundbreaking HIV pre-exposure prophylaxis injectable, has recently received FDA approval, marking a significant advancement in the fight against HIV. The approval is based on the compelling results of the 2024 PURPOSE 1 and PURPOSE 2 trials, which showcased the safety and efficacy of this innovative injectable across diverse populations and settings.
In the Phase 3 trials, Lenacapavir was tested on 5,338 cisgender women and adolescent girls aged 16-25 in South Africa and Uganda, with remarkable outcomes. The injectable demonstrated superior protection, with zero HIV infections reported among participants in the Lenacapavir group, in stark contrast to the 39 infections in the control group receiving oral pre-exposure prophylaxis drug Truvada. As Lenacapavir moves closer to EU approval, it heralds a new era in HIV prevention strategies.
Read more from thehindu.com